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A 74-year-old woman presented with edema in the lower extremities. Laboratory tests
revealed anemia, thrombocytopenia, hypoalbuminemia, hypercholesterolemia, and
nephrotic-range proteinuria. Myelodysplastic syndrome-refractory cytopenia with multi-
lineage dysplasia (MDS-RCMD) was conﬁrmed by bone marrow biopsy. Renal biopsy
demonstrated membranous glomerulonephritis (MGN), stage I. Based on these clinico-
pathologic results, she was diagnosed as having MGN with MDS-RCMD. This is a rare
case report of MGN in a parient with MDS-RCMD featuring nephrotic syndrome.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Myelodysplastic syndrome (MDS) is a stem-cell disorder
characterized by progressive impairment in the differentiation
of hematopoietic cells, resulting in a wide range of hematolo-
gic and clinical features [1]. Refractory cytopenia with multi-
lineage dysplasia (RCMD) is one of the subtypes of MDS,
according to the World Health Organization (WHO) classiﬁca-
tion [2]. Only a few cases of glomerulonephritis associated
with MDS have been demonstrated [3–9]. However, most of
them were reported in chronic myelomonocytic leukemia
(CMML), which is not currently included in the MDS category
[2]. We herein report a case of membranous glomerulone-
phritis (MGN) with MDS-RCMD featuring nephrotic syndrome.Case report
A 74-year-old woman was admitted to Yonsei University
Health System for evaluation of edema in her lowerean Society of Nephrology. Pub
y-nc-nd/4.0/).
al Medicine, College of
ng, Seodaemoon-Gu,
.extremities, which lasted for 2 months. She did not have any
speciﬁc medical history prior to admission. On physical exam-
inations, pale conjunctiva and grade 3 pitting edema in lower
extremities were observed. Distended abdomen and shifting
dullness were also detected. Her blood pressure was 141/
88 mmHg, pulse rate 88 beats/min, respiratory rate
22 breaths/min, and body temperature 37.1 1C. Laboratory
studies were as follows: red blood cell count 1,540/μL, hemo-
globin 4.9 g/dL, hematocrit 16%, white blood cell count 7,070/
μL (neutrophil 76%, lymphocyte 19%, and monocyte 4%),
platelet count 25,000/μL, and corrected reticulocyte count
0.71%. Peripheral blood smear showed macrocytic hypochro-
mic anemia with moderate anisopoikilocytosis, and giant
platelets were present. Laboratory results were as follows:
serum total protein, 4.7 mg/dL; albumin, 1.6 mg/dL; blood urea
nitrogen, 29.5 mg/dL; creatinine, 0.94 mg/dL; total cholesterol,
315 mg/dL; vitamin B12, 1741 pg/mL; folate, 6.37 ng/mL; C-
reactive protein, 2.91 mg/dL; and lactate dehydrogenase,
675 IU/L. Urine analysis revealed 4+ proteinuria and micro-
scopic hematuria (RBC 5-10/HPF). Random urine protein to
creatinine ratio was 9.34. The quantitative amount of urinary
protein for 24 hours was 14 g. In immunologic tests, anti-
nuclear antibody (ANA) was positive (1:160, mixed pattern)
and other autoimmune antibodies were normal. Serum C3 waslished by Elsevier. This is an open access article under the CC BY-NC-ND
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esis showed that the levels of immunoglobulin (Ig) A (748 mg/
dL) and IgM (240.6 mg/dL) were elevated.
Bone marrow biopsy showed hypercellular marrow (cellular-
ity: 80–90%). Blast cells were 0.8% of the total absolute neutrophil
counts. Dyspoietic erythroid precursors were present in about
10–15% (Fig. 1A). Ringed sideroblasts were observed in 20–25% of
erythroblasts. Megakaryocytes were markedly increased in num-
ber and megakaryocytic abnormality was seen (Fig. 1B). MDS-
RCMD was diagnosed according to the WHO classiﬁcation. Renal
biopsy demonstrated global sclerosis in one of the 13 glomeruli.
The remaining nonsclerotic glomeruli were normocellular with-
out mesangial expansion (Fig. 2). Immunoﬂuorescence revealed
diffuse granular deposition of IgG (2+) (Fig. 3A), C3 (1+) (Fig. 3B),Figure 1. Bone marrow aspirate ﬁnding. (A) Erythroid precursors
showed nuclear lobulation. (B) Increased number of megakaryocytes
with abnormal nuclei was seen. BM ﬁndings are suggested MDS-RCMD.
BM, bone marrow; MDS-RCMD, myelodysplastic syndrome-refractory
cytopenia with multilineage dysplasia.
Figure 2. Periodic acid staining. Normocellular glomeruli without
mesangial expansion were observed.
Figure 3. Immunoﬂuorescence results. Diffuse granular IgG(A), and C3
(B) deposits are seen along the peripheral capillary wall in glomerulus.and segmental linear deposition of ﬁbrinogen (1+) along the
peripheral capillary wall. Granular deposits of IgM (specks) were
detected in the mesangium. Electron microscopy showed podo-
cyte foot process effacement. The mesangium was not expanded
and had no electron-dense deposit. From these ﬁndings, a
diagnosis of MGN, Stage I, was made. On the basis of these
clinicopathologic ﬁndings, the patient was diagnosed as having
MGN with MDS-RCMD. She was managed with conventional
therapies for nephrotic syndrome, such as losartan (50 mg once a
day), rosuvastatin (20 mg once a day), furosemide (40 mg twice a
day), and spironolactone (100 mg once a day). After the ﬁnal
diagnosis was conﬁrmed, she was treated with oral prednisolone
(35 mg twice a day, 1 mg/kg) and then with decitabine (34 mg,
20 mg/m2). Cyclosporine (350 mg, 5 mg/kg) was added when the
ﬁrst cycle of decitabine was ﬁnished. After the second cycle of
decitabine, her hemoglobin and platelet levels were increased
and edema in lower extremities was improved. However,
nephrotic-range proteinuria remained. She was discharged with
tapered doses of prednisolone (15 mg once a day) and cyclos-
porine (150 mg once a day). Nephrotic-range proteinuria
remained 3 months later, without remission.Discussion
Glomerulonephritis is known to be associated with various
solid tumors, malignant lymphoma [10], and chronic lympho-
cytic leukemia [11]. Previous studies have reported an associa-
tion between solid tumors and MGN. In a cohort study of 240
patients with MGN, 24 (10%) patients had malignancy at the
time of renal biopsy or within a year thereafter [12]. The
incidence of cancer was signiﬁcantly higher in these patients
than in the general population. Moreover, an increased risk of
developing cancer was observed after the diagnosis of MGN. In
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Hodgkin's lymphoma is minimal change disease [10]. MGN or
membranoproliferative glomerulonephritis were reported in
patients with chronic lymphocytic leukemia [11].
MDS is characterized by abnormal bone marrow differentiation
andmaturation, cytopenia with normal or increased bone marrow
cellularity, morphologically and functionally changed progenitors,
and a variable risk of evolution to acute leukemia [1]. MDS had
been divided into ﬁve subtypes by the French–American–British
(FAB) classiﬁcation system since 1983. In 2002, the WHO classi-
ﬁcation reﬁned the deﬁnition of some subtypes to improve their
clinical relevance [2]. CMML was removed fromMDS category and
placed in a newly created group, myelodysplastic/myeloprolifera-
tive disease. RCMD is characterized by o5% bone marrow blasts
but with severe dysplasia in two more cell lineages.
Renal involvement in patients with MDS is rare, and there are
only sporadic reports of glomerulonephritis associated with MDS
[9]. In cohort studies of MDS patients, the frequency of clinical
glomerular disease has been reported to be 2 of 221 (0.9%) [5], 4 of
825 (0.48%) [4], and 5 of 125 (4%) [6]. A MEDLINE search revealed
that a total of 15 cases of clinical glomerular disease were
associated with MDS in adults [3–6,8]. MGN [5,8], crescentic
glomerulonephritis [4], atheroembolic renal disease [8], amyloi-
dosis [4], and mesangial proliferative glomerulonephritis with or
without mesangial IgA deposition [5–7] were reported. Among
them, nephrotic syndrome was presented in eight cases [3,4,6].
Nephrotic syndrome is more frequently reported in patients
with CMML than in those with other FAB subgroups. Paydas
et al [3] reported a case of nephrotic syndrome accompanying
anemia–thrombocytopenia in 1995. Splenomegaly and bone
marrow inﬁltrated by monocytic cells supported the diagnosis
of CMML. Renal biopsy revealed MGN. In the study of 825 de
novo MDS patients, nephrotic syndrome was diagnosed in
three individuals and they all fulﬁlled the diagnostic criteria
for CMML, including blood and bone marrow monocytosis [4].
Renal biopsy was performed in only one patient and AL
amyloidosis was conﬁrmed. Saitoh et al [6] reported that three
of 125 MDS patients had nephrotic syndrome. These three
patients were diagnosed as having CMML.
However, most of the above cases were reported prior to
2002, and the FAB classiﬁcation was applied to the diagnosis of
MDS. As CMML has been eliminated from MDS category since
2008, this case is a rare report of MGN with MDS-RCMD
according to the WHO classiﬁcation.
From the literatures, nephrotic syndrome in CMML may be
associated with monocytosis. Glomerular inﬁltration of mono-
cytes was observed in different types of glomerulopathy, and
the monocyte count was correlated to the activity of glomer-
ulopathy [13]. It was also reported that increased serum and
urine lysozyme levels may lead to tubular dysfunction and
induction of interstitial nephritis [4]. Increased serum and
urinary lysozyme levels are characteristic of monocytic leuke-
mia. Tumor necrosis factor-α, a cytokine mainly produced by
monocytes, was suspected to be a main cause of nephrotic
syndrome. Serum tumor necrosis factor-α levels in CMML
patients were higher than those in patients with other sub-
groups [14]. Based on these ﬁndings, it can be suggested that
the glomerular inﬁltration of monocytes may play a role in the
development of nephrotic syndrome with CMML.
Because nephrotic syndrome in MDS-RCMD has rarely been
reported, the pathogenesis remains unknown. Moreover, the
heterogeneity of the glomerular lesions in MDS implies that the
pathogenesis is unlikely to be uniform. As monocytosis is notfound in MDS-RCMD, the pathogenesis is different, with nephro-
tic syndrome with CMML possibly being involved in the devel-
opment of nephrotic syndrome in RCMD patients. One possible
candidate is an abnormal immunologic function. Paraneoplastic
autoimmune phenomena have been associated withMDS, includ-
ing acute systemic vasculitis syndrome, autoimmune disorders,
classical connective tissue disease, and most frequently relapsing
polychondritis [5]. A pathogenic role has been ascribed to
“immune dysregulation,” leading to a wide spectrum of distur-
bances in macrophage/monocyte, T cell, and B cell functions.
Immunologic abnormalities in both cell-mediated and humoral
immune systems have been known in MDS patients [7]. Various
immunological abnormalities, including defective B and T cell
immunity, hyper- or hypogammaglobulinemia, autoantibodies,
and complement disturbances, have been reported in MDS [9].
Furthermore, a considerable reduction in natural killer cell
activity has also been found in peripheral blood of MDS patients
[15]. Lastly, ANA was positive and serum levels of IgA and IgM
were elevated in our patient. Although the mechanism remains
unclear, these ﬁndings suggest that positive ANA is related to
paraneoplastic autoimmune phenomena. Increased IgA and IgM
levels are capable of activating complement, and immune com-
plex deposit is known to be the major pathogenesis of MGN.
Nevertheless, the possibility exists that nephrotic syndrome
and MDS-RCMD occurred coincidentally. Hence, further stu-
dies regarding the pathogenesis of nephrotic syndrome in
MDS-RCMD will be required.Conﬂicts of interest
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